A Phase 2 interventional study of SL-BUP and XR-BUP in Opioid Use Disorder (OUD), sponsored by NYU Langone Health. Active, not recruiting at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by NYU Langone Health · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies testing buprenorphine in Opioid-Related Disorders — 19 open to participants now, 21 under way, 5 of them phase 3. Buprenorphine · Opioid-Related Disorders.
Among the 173 studies testing buprenorphine in Opioid-Related Disorders, this one is the 2nd largest by enrollment of the 172 interventional ones that give a count, is one of 5 that started in 2021, is one of 52 in phase 2, reaches primary completion later than 3 of the 20 other live ones, and was the 142nd registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →19 of the 173 studies testing buprenorphine in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 19+
Pouya Azar · Sites in Canada
Ages 19+
Rachel R. Luba · Sites in United States
Ages 18–65
Lifespan · Sites in United States
Ages 18+
By country, each count listing its studies:
Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 66 · Phase 3 47 · Phase 4 41
First in 1988; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,516 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 19 across the 172 interventional studies. Of the 139 that completed or were terminated, 49 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 173 have an industry lead sponsor. The 10 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
23 studies in Opioid-Related Disorders by NYU Langone Health: 4 open now, 5 under way, 1 of them phase 3. Of 16 finished, 9 (56%) have results posted.
Among the 23 studies in Opioid-Related Disorders by NYU Langone Health, this one is the 2nd largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2021, is one of 3 in phase 2, and was the 16th registered.
NYU Langone Health’s Opioid-Related Disorders studies by the year they started, since 2010.
10 of the studies testing buprenorphine in Opioid-Related Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05011266Phase 3New York State Psychiatric InstituteEfficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder | 2027-01-01 |
| NCT06316830Phase 3Rhode Island HospitalIdentifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose | 2027-08-01 |
| NCT06494904Phase 3Yale UniversityStandard Versus High Dose ED-Initiated Buprenorphine Induction | 2027-09 |
| NCT06051890NYU Langone HealthAssessing Optimal XRB Initiation Points in Jail | 2026-12-01 |
| NCT04464980NYU Langone HealthOptimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 173 studies testing buprenorphine in Opioid-Related Disorders, from their registry updates:
Among NYU Langone Health’s 23 in Opioid-Related Disorders:
This tab as a report to print or save as PDF → With an account.
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
The main objectives of this study are:
The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.
Inclusion Criteria for Retention Phase:
Exclusion Criteria for Retention Phase:
Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:
Inclusion Criteria for Discontinuation Phase:
Exclusion Criteria for Discontinuation Phase:
Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: SL-BUP · Behavioral: MM
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: SL-BUP · Behavioral: MM
Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: XR-BUP · Behavioral: MM
Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: XR-NTX · Behavioral: MM
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: SL-BUP · Behavioral: MMR
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: SL-BUP · Behavioral: MMR
Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: XR-BUP · Behavioral: MMR
Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: XR-NTX · Behavioral: MMR
Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: SL-BUP · Behavioral: MM
Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: XR-BUP · Behavioral: MM
Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: XR-BUP · Behavioral: MM
Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.
Drug: XR-NTX · Behavioral: MM
Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: SL-BUP · Behavioral: MMD
Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: XR-BUP · Behavioral: MMD
Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: XR-BUP · Behavioral: MMD
Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.
Drug: XR-NTX · Behavioral: MMD
Daily dosing of sublingual buprenorphine-naloxone
Also known as: sublingual buprenorphine, Suboxone
Weekly/monthly dosing of extended-release injectable buprenorphine
Also known as: extended-release buprenorphine, CAM2038, Brixadi
Monthly dosing of extended-release injectable naltrexone
Also known as: extended-release naltrexone, Vivitrol
MM consists of standard Medical Management and the usual counseling at the treatment program.
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.
Retention: Continuous retention in MOUD treatment through 26 weeks
Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period.
Time frame: Retention: from randomization through week 26
Discontinuation: Completed Discontinuation without Relapse
Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued.
Time frame: Discontinuation: from randomization through week 24 follow up
Retention KS1: Weekly opioid abstinence
Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26.
Time frame: Retention: from randomization through week 26
Retention KS2: Treatment effectiveness
Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26.
Time frame: Retention: at week 26
Retention KS3: Treatment by baseline severity
Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no).
Time frame: Retention: at week 26
Discontinuation KS1: Completed Discontinuation
Completed Discontinuation without regard to relapse status
Time frame: Discontinuation: from randomization through week 24 follow up
Discontinuation KS2: Relapse
Relapse - separate binary outcome without regard to discontinuation status
Time frame: Discontinuation: from randomization through week 24 follow up
Discontinuation KS3: Safety
Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal.
Time frame: Discontinuation: from randomization through week 24 follow up
Discontinuation KS4: Treatment effectiveness
Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint).
Time frame: Discontinuation: at end of taper (EoT) and week 24 follow up
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy). Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/. The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Data sharing details ↗ · datashare.nida.nih.gov
Started Jun 2021 (actual). Primary completion is estimated for Dec 2026, 66 months after the start.
Of 61 non-industry phase 2 interventional studies under Opioid-Related Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 55. This study's planned 66 months is above that.
Counting every sponsor, half of 68 studies reached it within 40 months; a quarter within 23 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Buprenorphine · CAM2038 · Naltrexone